Apigenin in Increasing Health Benefits in High Risk Breast Clinic Patients (NCT03139227) | Clinical Trial Compass
WithdrawnNot Applicable
Apigenin in Increasing Health Benefits in High Risk Breast Clinic Patients
Stopped: PI decision
0Started 2017-08-15
Plain-language summary
This pilot clinical trial studies the side effects and best dose of apigenin in increasing health benefits in high risk breast clinic patients. Celery is high in apigenin, a compound that may have anti-cancer activities. Eating a celery-based diet may help in prevention and treatment of inflammatory diseases including cancer.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients should be followed in Stefanie Spielman Comprehensive Breast Center (SSCBC) High Risk Breast Clinic
* No known allergy to ingredients of banana bread preparation (eggs, almonds and other nuts since the celery also has almond powder)
* Must be \> 1 year from pregnancy, lactation or chemotherapy
* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
* Ability to give informed consent
* Participate in the specified study visits and laboratory testing including three (20 mL) blood draws and three 24 hour urine collections
Exclusion Criteria:
* Concurrent malignancy or metastatic malignancy of any kind
* Ongoing chemotherapy, radiation therapy, or other cancer-related treatment
* Current and past history of hypertension
* Chronic use of any herbal or dietary supplement containing apigenin within the 3 months prior to entry on the study
* Pregnant or nursing women
* Concurrent use of tamoxifen, raloxifene, or any of the aromatase inhibitors
What they're measuring
1
Apigenin levels in blood and urine
Timeframe: Up to 14 days
Trial details
NCT IDNCT03139227
SponsorOhio State University Comprehensive Cancer Center